Sign in or create an account to add this stock to your watchlist.
About Vectura Group (LON:VEC)
Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company's marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions. Its generic products include VR315, VR506, and VR632 for the treatment of asthma; and Phase III clinical stage products include VR475 for the treatment of severe adult asthma, and VR876 for the treatment of lung diseases, as well as NVA237 and QVA149 for the treatment of COPD for which filed NDA to the Food and Drug Administration. Its Phase II clinical stage products comprise VR096 for anti-inflammatory asthma and COPD; VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; and VR736 for the treatment severe influenza. The company's Phase I clinical stage products include VR942 for the treatment of asthma; VR475 for the treatment of severe adult asthma; and VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage product includes VR588 for the treatment of inflammatory airway diseases. The company also provides patent-protected technology platforms, such as PowderHale, a formulation technology that is designed to enhance the performance of inhaled formulations; PowderMax, a technology that applies PowderHale approach to create high performance dry powder formulations; and ParticleMax, spray drying particle engineering technology to deliver dry powder biologics. In addition, it provides dry powder inhalers; nebulizer delivery systems; and AKITA Jet, APIXNEB, and FOX devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:VEC
CUSIPN/A
Phone+44-1249-667700
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-48.35%
Return on Equity-11.44%
Return on Assets-9.24%
Miscellaneous
EmployeesN/A
Outstanding Shares679,350,000
Vectura Group (LON:VEC) Frequently Asked Questions
What is Vectura Group's stock symbol?
Vectura Group trades on the London Stock Exchange (LON) under the ticker symbol "VEC."
What price target have analysts set for VEC?
9 Wall Street analysts have issued 12-month price targets for Vectura Group's stock. Their forecasts range from GBX 105 to GBX 160. On average, they expect Vectura Group's stock price to reach GBX 134.56 in the next twelve months. View Analyst Ratings for Vectura Group.
Who are some of Vectura Group's key competitors?
Some companies that are related to Vectura Group include Mayne Pharma Group (MYX), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Sinclair Pharma (SPH), Pharmaxis (PXS), NanoViricides (NNVC), Futura Medical (FUM), Cathay International Television (CTI), Sareum (SAR), N4 Pharma (N4P), China Pharma (CPHI) and Bayer (BAYN).
Who are Vectura Group's key executives?
Vectura Group's management team includes the folowing people:
- Mr. James Ward-Lilley BA, MBA, CEO & Exec. Director (Age 53)
- Mr. Andrew Derodra, CFO & Exec. Director (Age 52)
- Elizabeth Knowles, Director of Investor Relations & Analysis
- Mr. John Murphy, Gen. Counsel & Company Sec. (Age 65)
- Fleur Wood, Director of Communications
Has Vectura Group been receiving favorable news coverage?
Headlines about VEC stock have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vectura Group earned a coverage optimism score of 0.05 on Accern's scale. They also assigned media stories about the company an impact score of 46.55 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Vectura Group?
Shares of VEC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Vectura Group's stock price today?
One share of VEC stock can currently be purchased for approximately GBX 86.20.
How big of a company is Vectura Group?
Vectura Group has a market capitalization of £528.41 million.
How can I contact Vectura Group?
Vectura Group's mailing address is One Prospect West, CHIPPENHAM, SN14 6FH, United Kingdom. The company can be reached via phone at +44-1249-667700.
MarketBeat Community Rating for Vectura Group (VEC)
MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote "Outperform" if you believe VEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vectura Group (LON:VEC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Vectura Group in the last 12 months. Their average twelve-month price target is GBX 134.56The high price target for VEC is GBX 160 and the low price target for VEC is GBX 105. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.70 | 2.64 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 134.56 | GBX 134.56 | GBX 169.56 | GBX 189.67 |
Vectura Group (LON:VEC) Consensus Price Target History
Vectura Group (LON:VEC) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Vectura Group (LON:VEC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vectura Group (LON VEC) Insider Trading and Institutional Ownership History
Vectura Group (LON VEC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2018 | Andrew Derodra | Insider | Buy | 190 | GBX 79 | £150.10 | | |
| 2/14/2018 | Andrew Derodra | Insider | Buy | 211 | GBX 71 | £149.81 | | |
| 1/17/2018 | Andrew Derodra | Insider | Buy | 127 | GBX 118 | £149.86 | | |
| 12/8/2017 | Andrew Derodra | Insider | Buy | 153 | GBX 98 | £149.94 | | |
| 11/8/2017 | Andrew Derodra | Insider | Buy | 156 | GBX 96 | £149.76 | | |
| 10/6/2017 | Andrew Derodra | Insider | Buy | 142 | GBX 106 | £150.52 | | |
| 9/12/2017 | Bruno Angelici | Insider | Buy | 70,000 | GBX 99 | £69,300 | | |
| 9/8/2017 | Andrew Derodra | Insider | Buy | 158 | GBX 94 | £148.52 | | |
| 9/7/2017 | Andrew Derodra | Insider | Buy | 82,000 | GBX 90 | £73,800 | | |
| 8/4/2017 | Andrew Derodra | Insider | Buy | 135 | GBX 111 | £149.85 | | |
| 6/6/2017 | Andrew Derodra | Insider | Buy | 135 | GBX 111 | £149.85 | | |
| 5/5/2017 | Andrew Derodra | Insider | Buy | 105 | GBX 143 | £150.15 | | |
| 4/6/2017 | Andrew Derodra | Insider | Buy | 99 | GBX 152 | £150.48 | | |
| 2/6/2017 | Andrew Derodra | Insider | Buy | 111 | GBX 135 | £149.85 | | |
| 9/30/2016 | Andrew Derodra | Insider | Buy | 30,000 | GBX 138 | £41,400 | | |
| 9/27/2016 | Trevor Phillips | Insider | Sell | 240,841 | GBX 139 | £334,768.99 | | |
| 9/26/2016 | Bruno Angelici | Insider | Buy | 80,000 | GBX 143 | £114,400 | | |
| 7/7/2016 | Derodra,Andrew | Insider | Sell | 263,364 | GBX 152 | £400,313.28 | | |
| 6/17/2016 | Derodra,Andrew | Insider | Sell | 419,661 | GBX 154 | £646,277.94 | | |
| 6/13/2016 | Derodra,Andrew | Insider | Sell | 279,774 | GBX 157 | £439,245.18 | | |
| 7/7/2015 | Oakley,Andrew J. | Insider | Buy | 1,000 | GBX 180 | £1,800 | | |
| 1/15/2015 | Trevor Phillips | Insider | Sell | 171,777 | GBX 144.50 | £248,217.77 | | |
(Data available from 1/1/2013 forward)
Vectura Group (LON VEC) News Headlines
| Source: |
|
Vectura Group (LON:VEC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Vectura Group (LON VEC) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
